| 2022 | Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722 | ANNALS OF ONCOLOGY |
| 2021 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
| Journal of Liver Cancer (대한간암학회지) |
| 2018 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
| LUNG CANCER |
| 2015 | Nivolumab in NSCLC: latest evidence and clinical potential | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | LANCET ONCOLOGY |
| 2021 | Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2004 | NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status | HISTOPATHOLOGY |
| 2009 | NK 세포의 세포독성을 증가시키는 새로운 물질과 그 유도체들의 항암효과 및 작용기전
| Thesis |
| 2001 | NK/T 세포 림프종 환자에서 시행된 비골수제거성 조혈모세포이식
| 대한조혈모세포이식학회지 |
| 2019 | NLN Jeffries 시뮬레이션 이론의 분석 및 평가 | Journal of Korea Society for Simulation in Nursing (한국간호시뮬레이션학회지) |
| 2023 | NLRP3 Exacerbate NETosis-Associated Neuroinflammation in an LPS-Induced Inflamed Brain
| IMMUNE NETWORK |
| 2017 | NLRP3 Inflammasome Contributes to Lipopolysaccharide-induced Depressive-Like Behaviors via Indoleamine 2,3-dioxygenase Induction
| INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY |
| 2021 | Nlrp3, Csf3, and Edn1 in Macrophage Response to Saturated Fatty Acids and Modified Low-Density Lipoprotein
| KOREAN CIRCULATION JOURNAL |
| 2023 | NLRX1 knockdown attenuates pro-apoptotic signaling and cell death in pulmonary hyperoxic acute injury
| SCIENTIFIC REPORTS |
| 2008 | NM23 as a prognostic biomarker in ovarian serous carcinoma
| MODERN PATHOLOGY |
